References
  1. Onitsuka T, Hirano Y, Nakazawa T, et al. Toward recovery in schizophrenia: current concepts, findings, and future research directions. Psychiatry Clin Neurosci (In press)
  2. McCutcheon RA, Reis Marques T, Howes OD.Schizophrenia-An Overview. JAMA Psychiatry. 2020; 77 : 201-10.
  3. Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999; 40 : 407-14
  4. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002; 159 : 1534-40.
  5. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330 : 445.
  6. Goff DC. The Pharmacologic Treatment of Schizophrenia-2021. 2021;325 : 175–6.
  7. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010; 36 : 71-93.
  8. Hasan A, Wobrock T, Gaebel W, et al. Germany Society of Psychotherapy and Psychosomatics (DGPPN); German Association of Psychiatry. Nervenarzt. 2013; 84 : 1359-60, 1362-4, 1366-8.
  9. NICE. Psychosis and schizophrenia in adults: the NICE guideline on treatment and
management. NICE Clinical Guideline 178. 2014 https://www.nice.org.uk/guidance/cg178 (accessed March 29, 2022).
  1. Remington G, Addington D, Honer W, et al. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017;62 : 604-16.
  2. Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: ”Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacol Rep. 2021; 41 : 266-324.
  3. Halfdanarson O, Zoega H, Aagaard L, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017; 27 : 1064–76.
  4. Toto S, Grohmann R, Bleich S, et al. Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. Int J Neuropsychopharmacol. 2019; 22 : 560-73.
  5. Kochi K, Sato I, Nishiyama C, et al. Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf. 2017; 26 : 642–56.
  6. Suzuki T, Uchida H, Tanaka KF, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol. 2003;18 : 323–9.
  7. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009; 67 : 110-7.
  8. Shakir M, Willems AE, van Harten PN, et al. The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial). Schizophr Res. 2022; 243 : 187-94.
  9. Keith SJ, Matthews SM. The diagnosis of schizophrenia: a review of onset and duration issues. Schizophr Bull. 1991; 17 : 51-67.
  10. Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013; 150 : 3-10.
  11. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015; 69 : 440-7.
  12. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004; 30 : 193-217.
  13. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001; 50 : 898-911
  14. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68 : 1751-62.
  15. Yasui-Furukori N, Muraoka H, Hasegawa N, et al. Association between the examination rate of treatment-resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep. 2022; 42 : 3-9.
  16. Buchanan RW, Kreyenbuhl J, Zito JM, et al. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry. 2002; 159 : 1035-43.
  17. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem. 2004; 11 : 313-27.
  18. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One. 2008;3 : e3150.
  19. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002; 106 : 323-30.
  20. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. 2002; 106 : 321-2.
  21. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007; 89 : 91-100.
  22. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188 : 122-7.
  23. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002; 63 : 93-4.
  24. Hashimoto N, Yasui-Furukori N, Hasegawa N, et al.Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr. 2021;63 : 102744.
  25. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009; 67 : 110-7.
  26. Chong MY, Tan CH, Fujii S, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004; 58 : 61-7.
  27. Georgiou R, Lamnisos D, Giannakou K. Anticholinergic burden and cognitive performance in patients with schizophrenia: A Systematic Literature Review. Front Psychiatry. 2021; 12 : 779607.
  28. Rodríguez-Ramallo H, Báez-Gutiérrez N, Prado-Mel E, et al.Association between Anticholinergic Burden and Constipation: A Systematic Review. Healthcare (Basel). 2021; 9 : 581.
  29. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010; 23 : 103-11.
  30. Hinkelmann K, Yassouridis A, Kellner M, et al. No effects of antidepressants on negative symptoms in schizophrenia. J Clin Psychopharmacol. 2013; 33 : 686-90.
  31. Stroup TS, Gerhard T, Crystal S, et al. Comparative effectiveness of adjunctive psychotropic medications in patients with schizophrenia. JAMA Psychiatry. 2019; 76 : 508-15.
  32. Sim F, Sweetman I, Kapur S, et al. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol. 2015; 29 : 212-23.
  33. Dold M, Li C, Gillies D, Leucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol. 2013; 23 : 1023-33.
  34. Carton L, Cottencin O, Lapeyre-Mestre M, et al. Off-Label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. Curr Pharm Des. 2015; 21 : 3280–97.
  35. Marston L, Nazareth I, Petersen I, et al. Prescribing of antipsychotics in UK primary care: a cohort study. 2014; 4 : e006135-2014-006135
  36. Morrens M, Destoop M, Cleymans S, et al. Evolution of first-generation and second-generation antipsychotic prescribing patterns in Belgium between 1997 and 2012: A population-based Study. J Psychiatr Pract. 2015; 21 : 248-58.
  37. Kuo CL, Chien IC, Lin CH. Trends, correlates, and disease patterns of antipsychotic use among elderly persons in Taiwan. Asia Pac Psychiatry. 2016; 8 : 278-86.
Figure legends Fig 1. These broken lines show the trend of the prescription rate of antipsychotics over time. Blue indicates monotherapy prescription rates for antipsychotics, orange indicates monotherapy prescription rates for second-generation antipsychotics (SGAs), gray indicates complete monotherapy use of psychotropic drugs, and yellow indicates complete monotherapy use of SGAs. Fig 2. The figure on the left shows the trend of chlorpromazine equivalent doses over time. Gray indicates doses of all antipsychotics, blue indicates doses of first-generation antipsychotics (FGA), and orange indicates doses of second-generation antipsychotics (SGA). The figure on the right shows the trend of equivalent doses of psychotropic drugs other than antipsychotics over time. Green indicates diazepam-equivalent doses of benzodiazepines, blue indicates imipramine-equivalent doses of antidepressants, and yellow indicates biperiden-equivalent doses of anticholinergics. Fig 3. This figure shows the trend over time of the percentage of first-generation antipsychotics (blue) and second-generation antipsychotics (orange) to chlorpromazine equivalent doses for all antipsychotics.